Diagnostic Value of Neutrophil to Lymphocyte Ratio in Non-Alcoholic Fatty Liver Disease Evaluated Using Transient Elastography (TE) with Controlled Attenuated Parameter (CAP)

References

• European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL–EASD–EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402. doi:10.1016/j.jhep.2015.11.004
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.
   PubMed Web of Science ®Google Scholar
• Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 2013;23:483–491. doi:10.1016/j.semcancer.2013.07.003
   PubMed Web of Science ®Google Scholar
• Lesmana CRA, Pakasi LS, Inggriani S, Aidawati ML, Lesmana LA. Development of non-alcoholic fatty liver disease scoring system among adult medical check-up patients: a large cross-sectional and prospective validation study. Diabetes Metab Syndr Obes Targets Ther. 2015;8:213–218. doi:10.2147/DMSO.S80364
   Web of Science ®Google Scholar
• Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690. doi:10.1038/nrgastro.2013.171
   PubMed Web of Science ®Google Scholar
• Milic S, Lulic D, Stimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20(28):9330–9337. doi:10.3748/wjg.v20.i28.9330
   PubMed Web of Science ®Google Scholar
• Sapmaz F, Uzman M, Basyigit S, Ozkan S, Yavuz B, Yeniova A. Steatosis grade is the most important risk factor for development of endothelial dysfunction in NAFLD. Med. 2016;95(14):1–7.
   Web of Science ®Google Scholar
• Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003;52(2):288–292. doi:10.1136/gut.52.2.288
   Web of Science ®Google Scholar
• Tao X, Liu Q, Wang Z. Metabolic syndrome is a risk factor for nonalcoholic fatty liver disease: evidence from a confirmatory factor analysis and structural equation modeling. Eur Rev Med Pharmacol Sci. 2016;20:4313–4321.
   Web of Science ®Google Scholar
• Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9–19.
   PubMed Web of Science ®Google Scholar
• Abd El-Kader SM, El-den Ashmawy EMS. Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol. 2015;7(6):846–858. doi:10.4254/wjh.v7.i6.846
   PubMed Web of Science ®Google Scholar
• Shiha G, Ibrahim A, Helmy A, Sarin SK, Omata M, Kumar A. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017;11(1):1–30. doi:10.1007/s12072-016-9760-3
   PubMed Web of Science ®Google Scholar
• Asil M, Dertli R. The neutrophil-to-lymphocyte ratio as a noninvasive marker in patients with biopsy-proven non-alcoholic steatohepatitis. Istanbul Med J. 2016;131–135. doi:10.5152/imj.2016.74755
   Google Scholar
• Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825–1835. doi:10.1016/j.ultrasmedbio.2010.07.005
   PubMed Web of Science ®Google Scholar
• Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58(5):1007–1019. doi:10.1016/j.jhep.2012.11.021
   PubMed Web of Science ®Google Scholar
• Abdel-Razik A, Mousa N, Shabana W, Refaey M, ElMahdy Y, Elhelaly R. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients. Eur J Gastroenterol Hepatol. 2016;28(1):e1–e9. doi:10.1097/MEG.0000000000000486
   PubMed Web of Science ®Google Scholar
• Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2011;5(2):189–200. doi:10.1586/egh.11.21
   PubMed Web of Science ®Google Scholar
• Meli R, Raso GM, Calignano A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5(4):1–14. doi:10.3389/fimmu.2014.00177
   Web of Science ®Google Scholar
• Mohamed NR, Assem M, Atef A, et al. Neutrophil to lymphocyte ratio as a new marker for predicting steatohepatitis in patients with nonalcoholic fatty liver disease. Int J Adv Res. 2015;3(10):688–697.
   Google Scholar
• Yilmaz H, Yalcin KS, Namuslu M, Celik HT, Sozen M, Inan O. Neutrophil-lymphocyte ratio (NLR) could be better predictor than C-reactive protein (CRP) for liver fibrosis in non-alcoholic steatohepatitis (NASH). Ann Clin Lab Sci. 2015;45(3):278–286.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TAR, Yerian L. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32(2):297–302. doi:10.1111/j.1478-3231.2011.02639.x
   PubMed Web of Science ®Google Scholar
• Kara M, Dogru T, Genc H, Sertoglu E, Celebi G, Gurel H. Neutrophil-to-lymphocyte ratio is not a predictor of liver histology in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27(10):1144–1148. doi:10.1097/MEG.0000000000000405
   PubMed Web of Science ®Google Scholar
• Malhotra P, Marwaha N, Marwaha S, Malhotra V, Malhotra N. Non-invasive biomarkers vs liver biopsy in diagnosing and staging NAFLD. Adv Res Gastroentero Hepatol. 2015;1(2):555559. doi:10.19080/ARGH.2015.01.555559
   Google Scholar
• De Ledinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart JB, Cassinotto C. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60(5):1026–1031. doi:10.1016/j.jhep.2013.12.018
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan Q, Wang T, Wen J, Wang H, Zhang T. Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. Int J Clin Exp Med. 2015;8(10):17654–17663.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006. doi:10.1016/j.dld.2015.08.004
   PubMedGoogle Scholar
• Summart U, Thinkhamrop B, Chamadol N, Khuntikeo N, Songthamwat M, Kim C. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: a population-based cross-sectional study. F1000research. 2017;6:1–17. doi:10.12688/f1000research.12417.1
   Google Scholar
• Bertot LC, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5):774.
   Web of Science ®Google Scholar
• Ryu S, Suh B, Chang Y, Kwon M, Eun K, Jung H. European journal of obstetrics and gynecology and reproductive biology menopausal stages and non-alcoholic fatty liver disease in middle-aged women. Eur J Obstet Gynecol. 2015;190:65–70. doi:10.1016/j.ejogrb.2015.04.017
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease in meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Wei Y, Tian Q, Zhao X, Wang X. Serum transforming growth factor beta 3 predicts future development of nonalcoholic fatty liver disease. Int J Clin Exp Med. 2015;8(3):4545–4550.
   Web of Science ®Google Scholar
• Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol. 2016;22(32):7236–7251. doi:10.3748/wjg.v22.i32.7236
   PubMed Web of Science ®Google Scholar
• Kanwar P, Nelson JE, Yates K, Kleiner DE, Unalp-Arida A, Kowdley KV. Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol. 2016;3(1):e000114. doi:10.1136/bmjgast-2016-000114
   Google Scholar